GlassScriptPhysician profile
Marcia Canto
NPI 1992763015
$7,180.76
in general payments reported to CMS, 2019-2025
24 companies · $465 in 2025
The $465 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $33.75 · 2021: $387 · 2022: $1,272 · 2023: $458 · 2024: $3,409 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,466 · Consulting Fee: $1,125 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,466.44 |
| Consulting Fee | $1,125.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $740.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $3,618.47 | 2019-2025 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Medtronic, INC. | $949.63 | 2021-2023 | Endoflip, Gi Genius, Bravo |
| Cook Medical LLC | $609.71 | 2022-2024 | Echotip, Echotip Insight |
| Endogastric Solutions, INC | $397.38 | 2019-2022 | |
| Fujifilm Healthcare Americas Corporation | $290.85 | 2024-2025 | Fujifilm |
| Abbvie INC. | $260.18 | 2019-2024 | Linzess, Viberzi, Creon |
| Regeneron Healthcare Solutions, INC. | $212.20 | 2022-2025 | Dupixent |
| Olympus America INC. | $147.15 | 2022 | |
| Qol Medical, LLC | $106.80 | 2024 | Sucraid |
| Boston Scientific Corporation | $105.83 | 2019 | |
| Erbe USA INC | $98.25 | 2025 | Apc |
| Takeda Pharmaceuticals U.S.A., INC. | $97.42 | 2021-2023 | Entyvio |
| Aimmune Therapeutics, INC. | $38.70 | 2024 | |
| Celltrion USA INC. | $35.24 | 2024-2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $33.94 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $28.35 | 2025 | Voquezna |
| Janssen Biotech, INC. | $25.17 | 2025 | Tremfya |
| Daiichi Sankyo INC. | $23.97 | 2019 | |
| Exact Sciences Corporation | $23.23 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.69 | 2023 | Cyltezo |
| Pfizer INC. | $20.84 | 2023 | |
| Shionogi INC | $14.47 | 2019 | |
| Lucid Diagnostics INC. | $13.00 | 2021 | |
| Ambu INC. | $8.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcia Canto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.